Although several genetic alterations, such as the mutation status of KRAS and BRAF genes or microsatellite instability (MSI), represent prediction factors for CRC progression, they are not sufficient for predicting treatment responses in metastatic CRC. This evidence concerns the gene BRAF and colorectal carcinoma.